Skip to content
Review Open access

Rescue Transcatheter Aortic Valve Implantation for Severe Native Aortic Regurgitation in a Young Patient with Hypertrophic Obstructive Cardiomyopathy and Cardiogenic Shock: Review of the Literature and Case Presentation

Sep 2026 · Life · Vol 16 · 0 citations · 46 references
Medicine

TL;DR

Current evidence on TAVI for native AR focuses on devices, procedural performance, complications, and outcomes, and presents a 24-year-old man with MYH7-associated hypertrophic obstructive cardiomyopathy and severe post-myectomy AR complicated by biventricular failure, cardiogenic shock, and multiorgan dysfunction.

Abstract

Transcatheter aortic valve implantation (TAVI) for pure native aortic regurgitation (AR) remains technically challenging, primarily because absent annular calcification limits prosthesis anchoring. We reviewed contemporary evidence on TAVI for native AR, focusing on devices, procedural performance, complications, and outcomes. A comprehensive PubMed search identified 371 articles, of which 28 studies comprising 3282 patients met the inclusion criteria; notably, 64.3% were published from 2023 onward, reflecting the rapidly expanding evidence in this field. Conventional off-label devices were evaluated in 60.7% of studies and dedicated AR devices in 35.7%, while 3.6% directly compared both strategies. Technical/device success ranged from 72% to 100%, generally exceeding 85–90% in contemporary series, while 30-day mortality ranged from 0% to 23%. To illustrate the technical challenges and expand this evidence, we present a 24-year-old man with MYH7-associated hypertrophic obstructive cardiomyopathy and severe post-myectomy AR complicated by biventricular failure, cardiogenic shock, and multiorgan dysfunction. Given prohibitive surgical risk, rescue transfemoral TAVI was performed. Despite embolization of the first balloon-expandable prosthesis, a second valve was successfully implanted using an individualized anchoring strategy. At 1 year, the patient was in NYHA class I with biventricular recovery. TAVI represents an evolving alternative for carefully selected patients with severe native AR and prohibitive surgical risk.

Read PDF

Similar papers

Open access Aug 2026

Early Multicenter Outcomes of Dedicated Transcatheter Aortic Valve Replacement for Left Ventricular Assist Device‐Associated Pure Aortic Regurgitation

ABSTRACT Background Aortic regurgitation (AR) is a frequent and clinically relevant complication in patients with left ventricular assist devices (LVAD), impairing circulatory support and worsening outcomes. Surgical aortic valve replacement often carries prohibitive risk in this population, while conventional transcat...

H. Hinkov, Sara Yousefzada, I. Just et al. · 0 citations
Sep 2026

Clinical Outcomes of a Dedicated TAVR Device for Native Aortic Regurgitation: Insights From a Multicenter Real-World Experience.

BACKGROUND The JenaValve Trilogy Transcatheter Heart Valve System (Trilogy) is a CE-marked transcatheter aortic valve replacement device designed for the treatment of symptomatic aortic regurgitation. Despite its unique indication, data from large cohorts remain limited. This study aimed to evaluate procedural characte...

H. Wienemann, Sara Yousefzada, M. Rogmann et al. · 0 citations
Open access Feb 2026

Transcatheter aortic valve-in-valve implantation for failed surgical aortic bioprostheses using the Navitor platform: early outcomes in a consecutive single-center cohort

Introduction Transcatheter heart valve implantation into a failed surgical heart valve (THV-in-SHV) is an established reintervention strategy for degenerated aortic bioprostheses; however, early procedural outcomes, discharge hemodynamics, and standardized safety remain clinically relevant in routine practice. Material...

R. Sobczyński, J. Trębacz, Paweł Kleczyński et al. · 0 citations
Review Open access Sep 2026

Clinical Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Pure Native Aortic Regurgitation: A Systematic Review and Meta-Analysis

Background: Aortic valve regurgitation is a common valvular heart disease. Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) are the principal therapeutic modalities, while the comparative efficacy of these two approaches remains controversial. Methods: This systematic review an...

Hong-Hong Ke, Shi-Rong Wang, Jin-Yi Li et al. · 0 citations
Review Sep 2026

TAVI in low‑risk severe aortic stenosis: evidence, controversies and lifetime treatment strategy.

Transcatheter aortic valve implantation (TAVI) has expanded from a treatment for inoperable and high-risk aortic stenosis (AS) to an established therapeutic option for selected patients at low surgical risk; this review focuses on the outcomes of major trials comparing TAVI to traditional surgical aortic valve replacem...

Kelly Wright, Arafat Rahman, Georgia Penny et al. · 0 citations
Review Open access 2026

Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Low Surgical Risk Patients With Severe Aortic Stenosis: A Literature Review

Aortic stenosis is among the most common valvular heart diseases and, if untreated, can lead to reduced quality of life and potential heart failure. Surgical Aortic Valve Replacement (SAVR) has long been recognized as the standard treatment for severe aortic stenosis, while Transcatheter Aortic Valve Replacement (TAVR)...

Dev Shah · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.